日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

FDA批准摘要:Pirtobrutinib用于治疗复发或难治性套细胞淋巴瘤

Telaraja, Deepti; Kasamon, Yvette L; Collazo, Justin S; Leong, Ruby; Wang, Kun; Li, Ping; Dahmane, Elyes; Yang, Yuching; Earp, Justin; Grimstein, Manuela; Rodriguez, Lisa R; Theoret, Marc R; Gormley, Nicole J

Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticles

利用免疫刺激性光热纳米粒子构建肿瘤特异性T细胞

Sweeney, Elizabeth E; Sekhri, Palak; Telaraja, Deepti; Chen, Jie; Chin, Samantha J; Chiappinelli, Katherine B; Sanchez, Carlos E; Bollard, Catherine M; Cruz, C Russell Y; Fernandes, Rohan

A Virtual Cardiovascular Care Program for Prevention of Heart Failure Readmissions in a Skilled Nursing Facility Population: Retrospective Analysis

一项针对养老院人群预防心力衰竭再入院的虚拟心血管护理计划:回顾性分析

Friedman, Daniel M; Goldberg, Jana M; Molinsky, Rebecca L; Hanson, Mark A; Castaño, Adam; Raza, Syed-Samar; Janas, Nodar; Celano, Peter; Kapoor, Karen; Telaraja, Jina; Torres, Maria L; Jain, Nayan; Wessler, Jeffrey D